The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.
Uschner FE, Schueller F, Nikolova I, Klein S, Schierwagen R, Magdaleno F, Gröschl S, Loosen S, Ritz T, Roderburg C, Vucur M, Kristiansen G, Lammers T, Luedde T, Trebicka J.
Uschner FE, et al. Among authors: schueller f.
Oncotarget. 2018 Nov 16;9(90):36220-36237. doi: 10.18632/oncotarget.26333. eCollection 2018 Nov 16.
Oncotarget. 2018.
PMID: 30546838
Free PMC article.